EVOFEM INC
PharmaEVOFEM INC is a pharmaceutical company focused on Infectious Disease. Key products include SOLOSEC.
FDA Novel Drug Designations
(2017)See 1 novel approval →
EVOFEM INC at a Glance
- Strong track record with 83% execution quality across 7 trials
- Fast trial execution (16 months median completion)
EVOFEM INC's Key Drugs
EVOFEM INC's core commercial portfolio centers on SOLOSEC, PHEXX, spanning Infectious Disease — its most strategically important drugs approved in the last 15 years.
EVOFEM INC's Recent FDA Approvals
New NDA/BLA approvals for EVOFEM INC over the last two years — novel drugs only, excluding generics and label supplements.
EVOFEM INC's Therapeutic Areas
EVOFEM INC's approved drugs and pipeline span 1 therapeutic area, led by Infectious Disease, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
EVOFEM INC's Top Competitors
EVOFEM INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
EVOFEM INC Pipeline Snapshot
EVOFEM INC has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 1 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • SOLOSEC leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 4/5 completed
- • Speed: 16 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges